Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Advanced Solid Tumors 3Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Solid Tumors 1Solid Malignancies 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Glioma 1

Interventions

Injections 25Carboplatin 17Docetaxel 14pembrolizumab 12Paclitaxel 11Bevacizumab 9durvalumab 8Cisplatin 8Nivolumab 6Fluorouracil 6trifluridine tipiracil drug combination 5tislelizumab 5linifanib 5Pemetrexed 5Oxaliplatin 5Leucovorin 5zimberelimab 4toripalimab 4talazoparib 4olaparib 4Itraconazole 4Irinotecan 4Gemcitabine 4Capecitabine 4tremelimumab 3sotorasib 3sintilimab 3fludarabine 3depatuxizumab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors × ST 1481 × Clear all
NCT00410358 2020-12-19

A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.

Novartis

Phase 1 Completed
19 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00441610 2020-12-19

An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor

Novartis

Phase 1 Completed
4 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00487058 2009-11-19

A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
28 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡